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 2009 EMBO Molecular MedicineVarious age-related neurodegenerative diseases, including Parkinson’s disease,
polyglutamine expansion diseases and Alzheimer’s disease, are associated withaccumulation of misfolded proteins in aggregates in the brain. How and why
se proteins form aggregates and cause disease is still poorly understood. Small
del organisms—the baker’s yeast Saccharomyces cerevisiae, the nematode worm
enorhabditis elegans and the fruit fly Drosophila melanogaster—have been used to
del these diseases and high-throughput genetic screens using these models have
to the identification of a large number of genes that modify aggregation and
icity of the disease proteins. In this review, we revisit these models and provide a
mprehensive comparison of the genetic screens performed so far. Our integrative
alysis highlights alterations of a wide variety of basic cellular processes. Not all
ease proteins are influenced by alterations in the same cellular processes and
spite the unifying theme of protein misfolding and aggregation, the pathology of
ch of the age-related misfolding disorders can be induced or influenced by a
ease-protein-specific subset of molecular processes.Introduction
Several age-related neurodegenerative
diseases, including Parkinson’s
disease, Alzheimer’s disease and Hun-
tington’s disease are associated withthe accumulation of misfolded proteins into microscopically
visible aggregates in the brain (see Fig 1). These aggregates
contain fibrillar structures that are mainly composed of disease-
specific misfolded proteins, such as a-synuclein in Parkinson’s
disease, amyloid-b and tau in Alzheimer’s disease, superoxide
dismutase (SOD) in Amyotrophic lateral sclerosis (ALS), and
mutant huntingtin in Huntington’s disease (Fig 1) (Masters et al,




sachusetts Generalet al., 1997). There is still controversy about the role of the
aggregates but the prevalent hypothesis is that they represent a
cellular protection mechanism against toxic aggregation inter-
mediates (Arrasate et al, 2004; Kaganovich et al, 2008; Lansbury
& Lashuel, 2006; Sanchez et al, 2003; Saudou et al, 1998).
Familial forms of these misfolding diseases often involve
toxic gain-of-function mutations that increase misfolding and
aggregation properties as well as the toxicity of the disease
proteins. This is well illustrated by Huntington’s disease, in
which expansion of a polyglutamine stretch within the
huntingtin protein causes disease. In this and several other
polyglutamine diseases, there is a direct correlation between the
length of the polyglutamine expansion and the aggregation
kinetics and toxicity of disease proteins (Scherzinger et al, 1997;
Chen et al, 2002). Additionally, there is an inverse correlation
between the length of the polyglutamine stretch and the age-at-
onset of disease (Gusella & MacDonald, 2006). Apart from theEMBO Mol Med 1, 360–370 www.embomolmed.org
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Tjakko J. van Ham et al.misfolding properties of the disease proteins, other inherited
factors are predicted to modify the age-at-onset of these familial
misfolding diseases (Rosenblatt et al, 2001).
Non-familial forms of neurodegenerative diseases, which
include the majority of cases of Parkinson’s and Alzheimer’s
disease, typically develop in old age. In these sporadic cases the
characteristic aggregates in the brain are primarily composed of
misfolded, but wild type, disease proteins. The cause of protein
misfolding and pathogenesis in these non-familial forms remains
elusive. One can speculate that several phenomena associated
with old age, for example cell shrinkage and a decline in protein
quality control, could cause or contribute to protein misfolding
and aggregation and thereby lead to disease (Gaczynska et al,
2001; Reznick & Gershon, 1979; Shtilerman et al, 2002). These
phenomena do not explain, however, why different people
develop different protein-misfolding diseases in old age. Other
disease-modifying factors are likely to play a role as well. Finding
the genetic modifiers that influence protein misfolding and
toxicity is, therefore, expected to expand our understanding of theGlossary
Age-at-onset of disease
The mean age at which a disease is revealed by its characteristic
symptoms.
Alzheimer’s disease
Age-related neurodegenerative disease, characterized pathologically
by protein aggregates known as plaques and tangles consisting
mainly of the proteins amyloid beta and phosphorylated tau. The
main symptoms are memory loss and reduced cognitive functioning.
Amyotrophic lateral sclerosis
Progressive, fatal, neurodegenerative disease caused by the degen-
eration of motor neurons resulting in loss of ability to initiate and
control all voluntary movement.
Essential genes
Genes that are required for (early) embryonic development, and loss
of which is lethal at an early stage.
Huntington’s disease
Heritable neurodegenerative disease, characterized pathologically by
loss of neurons and protein aggregates consisting mainly of mutant
Huntingtin protein. The main symptoms are involuntary movements
(chorea), declined mental abilities and behavioural and psychiatric
problems.
Lipid metabolism
The synthesis, breakdown and transport of various lipid-containing
molecules.
miRNA
microRNAs are small RNA molecules that regulate gene expression.
Molecular chaperone
Proteins that assist in the correct folding of other proteins and protect
against misfolding.
Parkinson’s disease
Age-related neurodegenerative disease, characterized pathologically
by protein aggregates in the brain, mainly composed of alpha-
synuclein known as Lewy bodies. The main symptoms are reduced
motor skills and movement defects.
www.embomolmed.org EMBO Mol Med 1, 360–370molecular cause(s) of protein-misfolding diseases and could
provide important cues for therapeutic strategies.
So far, human genetic screens and pathological studies have
been able to provide limited mechanistic insight into the
molecular processes that determine disease susceptibility or
age-at onset of disease (Carrasquillo et al, 2009; Lesage & Brice,
2009; Metzger et al, 2006; Mougeot et al, 2009). Small genetic
model organisms, transgenically expressing human misfolding
disease-related proteins, together with large-scale genetic screens,
have therefore been exploited to generate additional hypotheses
about protein-misfolding disease mechanisms (Bilen & Bonini,
2007; Fernandez-Funez et al, 2000; Ghosh & Feany, 2004; Giorgini
et al, 2005; Hamamichi et al, 2008; Kaltenbach et al, 2007;
Kazemi-Esfarjani & Benzer, 2000; Kraemer et al, 2006; Nollen
et al, 2004; Outeiro & Lindquist, 2003; Van Ham et al, 2008; Wang
et al, 2009a; Willingham et al, 2003). Here we describe these
models and provide a first integrative and comprehensive
comparison of the results of these large-scale screens. We aimed
to pinpoint evolutionary conserved processes with a role inProteasomal degradation
Proteolytic breakdown of damaged or superfluous proteins into short
peptides. In mammalian cells this is affected by the proteasome, a
large 2000 kDa enzymatic complex.
Protein quality control
The recognition and disposal of misfolded, damaged and no longer
required proteins.
RNA metabolism
The synthesis (transcription), breakdown and transport of ribonucleic
acids.
Sarcopenia
Degenerative loss of skeletal muscle tissue and skeletal muscle
strength as a consequence of aging.
Spinocerebellar ataxias
Progressive neurodegenerative diseases of the cerebellum, resulting in
motor coordination loss.
Superoxide dismutase
Important antioxidant defence enzymes that catalyse the dismutation
of superoxide into oxygen and hydrogen peroxide.
Synaptic vesicles
Small membrane-bounded compartments containing neurotransmit-
ters at the synapse of neurons.
Tau
Microtubule-associated protein abundant in neurons in the central
nervous system. Hyperphosphorylation of the tau protein can result in
self-assembly of fibrillary tangles involved in Alzheimer’s disease and
other tauopathies.
Vesicle trafficking
The movement of small membrane-bounded compartments (vesicles)
between organelles, such as from the ER to the Golgi system.
 2009 EMBO Molecular Medicine 361
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Figure 1. Protein aggregation in neurodegenerative disease. Examples of aggregation in brains of patients with neurodegenerative disorders (disorders in dark
blue). Typically, these aggregates contain amyloid-like fibrils composed of specific disease proteins (disease proteins in brown). All photographs provided by
Wilfred den Dunnen, UMCG, Groningen, The Netherlands.
362misfolding and to extract common and disease-specific processes,
which will provide a focus for future mechanistic studies and for
development of therapeutic strategies.Yeast, worm and fly models of
protein-misfolding disease
Small model organisms—baker’s yeast (Saccharomyces
cerevisiae), the nematode worm (Caenorhabditis elegans) and
the fruit fly (Drosophila melanogaster)—have been used to
model several aspects of neurodegenerative diseases, including
aggregation and toxicity of misfolding disease-related proteinsTable 1. Conservation of genetics of human disease in popular model organis
Proteins encoded i
Yeast (Saccharomyces cerevisiae) 6241
Worm (Caenorhabditis elegans) 18,424
Fruit fly (Drosophila melanogaster) 13,601
Mouse (Mus musculus) 26,258
Human (Homo sapiens) 20,000–25,0
‘Proteins encoded in genome’ indicates the estimated number of proteins encoded
et al (2000) were used, for mouse, the Mouse Genome Informatics from Jackso
estimation from the International Genome Sequencing Consortium. The human dis
disease genes, relating to the number of orthologues in that model organism of hu
genes (O’Brien et al, 2004, Human Mutation; http://orthodisease.cgb.ki.se).
 2009 EMBO Molecular Medicine(Fernandez-Funez et al, 2000; Ghosh and Feany, 2004;
Hamamichi et al, 2008; Kazemi-Esfarjani and Benzer, 2000;
Kraemer et al, 2006; Kuwahara et al, 2008; Morley et al, 2002;
Outeiro and Lindquist, 2003; Van Ham et al, 2008; Wang et al,
2009a). These organisms share at least 30% of their genes with
humans and show a strong evolutionary conservation of many
cellular pathways (Table 1). In fact, several regulatory pathways
that play a major role in human embryonic development and
physiology were first elucidated in these organisms, including
genetic pathways that regulate programmed cell death and
neuronal function (Ellis & Horvitz, 1986; McIntire et al, 1993). In
addition, molecular pathways that regulate aging have been
resolved in yeast, worms and flies, which makes these modelsms for protein aggregation research






by the genome; for yeast, C. elegans and Drosophila the estimations from Rubin
n Laboratory (jax.bioinformatics.org; September 2009), and for human the
ease homology indicates the number of genetic orthologue clusters to human
man disease genes, a measure for the genetic conservation of human disease
EMBO Mol Med 1, 360–370 www.embomolmed.org
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Table 2. Summary of genetic screens for modifiers of protein-misfolding toxicity and inclusion formation in small model organisms








Yeast 4850 deletion library (LOF) 6241 80 Htt103Q n.a. Toxicity Willingham
et al (2003)
1
4850 deletion library (LOF) 6241 80 Htt103Q n.a. Toxicity Giorgini
et al (2005)
2
C. elegans Genome-wide RNAi (LOF)a 18,424 89 Q35-YFP BWM Inclusion Nollen
et al (2004)
3
Drosophila 7000 P-element insertions
(LOF/GOF)




































Yeast 4850 deletion library (LOF) 6241 80 Alpha-syn n.a. Toxicity Willingham
et al (2003)
9





XS; 5,500 strain library (GOF) 6241 92 Alpha-syn n.a. Toxicity Yeger-Lotem
et al (2009)
11
C. elegans Genome-wide RNAi (LOF)a 18,424 89 Alpha-syn-YFP BWM Inclusions Van Ham
et al (2008)
12
1673 candidates RNAi (LOF)b 18,424 9 Alpha-syn Neurons Toxicity Kuwahara
et al (2008)
13






C. elegans Genome-wide RNAi (LOF)a 18,424 89 tau (337M-1) Neurons Toxicity Kraemer
et al (2006)
15
Genome-wide RNAi (LOF)a 18,424 89 SOD-G85R (þ/-YFP) Neurons Toxicity/
inclusions
Wang et al (2009a) 16
Screen setup indicates whether screen was performed using mutagenesis (deletion libraries, transposon based insertion), transgenic overexpression (XS) or
knockdown (RNAi, RNA interference). Estimations for the number of encoded proteins in the genome are based on Ruben et al (2000). The ‘percentage screened for’
indicates the number of genes screened for/manipulated (GOF and LOF) as a percentage of the predicted number of proteins. Toxicity and inclusions indicate
whether the screen included the formation of inclusions or the exertion of toxicity as a read for the screen, this does not indicate all genes screened for where
tested accordingly. BWM, body wall muscle; LOF, loss-of-function; GOF, gain-of-function; n.a., not applicable.
aGenome-wide RNAi screens correspond to the assaying of RNAi knockdown 17,000 genes using the Ahringer RNAi library (ref).
bCandidates based on previous findings. SOD, superoxide dismutase; mutation of which is involved in amyloid lateral sclerosis (ALS), Sca1/3 Spinocerebellar ataxia
genes 1/3.excellently suited to studying aging-associated neurodegenera-
tive diseases (Clancy et al, 2001; Kaeberlein et al, 1999; Kenyon
et al, 1993).
The misfolded protein pathology of human neurodegenera-
tive diseases has been modelled in these small model organisms
by transgenic expression of human disease proteins (Table 2,
Fig 2). As an example, expression of human a-synuclein in yeast
is toxic in a dose-dependent manner, resembling the situation in
humans in which multiplication of the a-synuclein locus causes
early-onset Parkinson’s disease (Ibanez et al, 2004; Outeiro and
Lindquist, 2003; Singleton et al, 2003). Similarly, worms
expressing fluorescently labelled polyglutamine stretches, show
a repeat-length dependent- and age-dependent aggregation andwww.embomolmed.org EMBO Mol Med 1, 360–370toxicity, which captures the inverse correlation between the
onset-age of disease and length of repeat expansion in human
polyglutamine diseases (Morley et al, 2002).
A major feature of all of these protein-misfolding diseases is
that they manifest late in life, usually after middle age. With
respect to this age dependency, an important practical
advantage of using small animal models is that, while they
do show a well-defined pathobiology of aging that resembles
that of humans, they do have a much shorter lifespan. C.
elegans, for example, lives for only about 20 days and shows
progressive cellular aging, including a deterioration of muscles
that resembles aging-related sarcopenia in humans (Herndon
et al, 2002). The short lifespan and defined aging properties 2009 EMBO Molecular Medicine 363
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Figure 2. Screening phenotypes in small model organisms related to
polyglutamine diseases.
A. Genetic suppression of toxicity in a fly eye. Adapted from Kazemi-Esfarjani
and Benzer (2000).
B. Genetic suppression of toxicity in yeast. Adapted from Giorgini et al (2005).
C. Enhancement of aggregation in worm body-wall muscle cells. Adapted
from Nollen et al (2004).
364of these model organisms enable the progressive stages of
age-related disease pathology to be monitored during all
developmental stages up to old age.
A link between the molecular mechanisms of aging and protein-
misfolding pathology has been found in these models; molecular
pathways that regulate the lifespan of these organisms also
influence progression of misfolding disease phenotypes (Cohen et
al, 2006; Morley et al, 2002; Outeiro et al, 2007; Van Ham et al,
2008). In sum, small model organisms are available that capture
paramount genetic features of protein-misfolding diseases, includ-
ing the age-dependent aggregation and toxicity of disease-related
proteins. These features can be modified by independent processes,
as illustrated by mutations in genes that regulate lifespan and alter
misfolded protein pathology. The ease of culturing and genetic
screening in yeast, worm and fly models of protein-misfolding
diseases means that these organisms are uniquely suited for the
unbiased identification of novel modifiers and cellular processes
involved in these aging-associated disease phenotypes.Genetic screens for modifiers of protein misfolding
and aggregation
To systematically identify modifiers of aggregation and toxicity
of misfolded disease proteins, yeast, worm and fly models have 2009 EMBO Molecular Medicinebeen used for a variety of high-throughput genetic screens,
ranging from deletion libraries to genome-wide RNAi screens
(Table 2 and Table 1 of Supporting Information). Some
researchers doubt the relevance of small model organisms for
identifying modifiers of human disease, but several observa-
tions demonstrate that the results can be extrapolated to human
neuronal cells. For example, in the C. elegans genome-wide
RNAi screen for polyglutamine aggregation, TCP-1 chaperonin
orthologues were identified as modifiers (Nollen et al, 2004).
Several studies later confirmed the role of this chaperonin in
aggregation of mutant huntingtin in mammalian cells, proving the
validity of such a screen to find bona fide candidate disease
modifiers (Behrends et al, 2006; Kitamura et al, 2006; Tam et al,
2006). Along the same line, the ER-Golgi transport regulator, Rab1,
picked up in a yeast screen as a suppressor of a-synuclein toxicity,
showed rescue of different toxicity phenotypes related to a-
synuclein in mammalian neurons as well, indicating that the
underlying processes are evolutionarily conserved (Cooper et al,
2006). Finally, the yeast orthologue of a Parkinson’s disease-linked
gene, ATP13A2, has been found as a modifier of a-synuclein
toxicity in yeast (Gitler et al, 2009). This finding has revealed a
functional connection between a-synuclein and another Parkin-
son’s disease susceptibility gene (Gitler et al, 2009). Together,
these examples demonstrate the potential of genome-wide screens
in simple organisms to provide insight into the molecular
mechanisms of neurodegenerative diseases in humans.
Screens in flies
The first high-throughput genetic screens for modifiers of
misfolded protein toxicity used transgenic Drosophila models
for polyglutamine (Fernandez-Funez et al, 2000; Kaltenbach
et al, 2007; Kazemi-Esfarjani and Benzer 2000). Expression of
mutant ataxin-1 (SCA1), ataxin-3 (SCA3), which cause
Spinocerebellar ataxias 1 and 3 in humans, or 127Q huntingtin
in neuronal retina cells causes depigmentation and collapse of
eye morphology (Fig 2) (Bilen and Bonini, 2007; Fernandez-
Funez et al, 2000; Kazemi-Esfarjani and Benzer, 2000). This
toxicity phenotype can be rescued by overexpression of heat
shock protein 70 (ASP7), an evolutionarily highly conserved
molecular chaperone involved in refolding of misfolded proteins
(Warrick et al, 1999). Using libraries of genetically altered
transposon (P-element) insertion strains, additional modifiers of
toxicity of polyglutamine proteins have been screened for. These
screens have identified Hsp70 co-chaperones, such as Hsp40
and DNAJ1, and genes involved in proteasomal degradation as
modifiers of toxicity (Bilen and Bonini, 2007; Fernandez-Funez
et al, 2000; Kazemi-Esfarjani and Benzer, 2000).
Screens in yeast
Comprehensive genetic screens in yeast have been performed
with libraries comprised of thousands of strains that have a
deletion in a single yeast gene or conversely overexpress one.
Genes that enhance or suppress toxicity of misfolded
a-synuclein or huntingtin proteins, as scored for by assessing
their influence on colony forming ability, were considered
modifiers of toxicity (Fig 2) (Cooper et al, 2006; Giorgini et al,
2005; Willingham et al, 2003). Classification of these genesEMBO Mol Med 1, 360–370 www.embomolmed.org
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in stress response pathways, protein folding and proteasomal
degradation. Modifiers of a-synuclein toxicity, on the other
hand, are overrepresented in vesicle-mediated transport and
lipid metabolism, suggesting that, in contrast to expectations
based on similarities between a-synuclein protein aggregation
pathology to other diseases, these disease proteins cause toxicity
via different mechanisms.
Screens in C. elegans
Finally, screens for modifiers in C. elegans have used genome-
wide RNAi libraries composed of about 17,000 bacterial strains
expressing double-stranded RNA against almost every C.
elegans gene. The worms can be fed these strains to knock
down each individual gene one by one. When applied after
embryonic development, such screens have the advantage that,
compared to yeast screens, they can also screen for essential
genes. Screens for modifiers of aggregation initially took
advantage of the transparency of C. elegans at all ages and
the amenability of the body wall muscle cells for RNAi. These
screens focused on identifying modifiers that caused a
premature appearance of microscopically visible aggregates of
fluorescently labelled misfolded proteins (Fig 2) (Nollen et al,
2004; Van Ham et al, 2008). A genome-wide RNAi screen for
modifiers of polyglutamine aggregation identified close to 200
modifiers. The majority of these fell into five functional classes:
translation, protein turnover, -folding and -transport and RNA
metabolism, which suggested that even small changes in a wide

















Screen numbers correspond to numbers and references in Table 2. Colour codin
publications (Table 1 of Supporting Information). White indicates that no genes in t
only found as one gene in one or two screens, without functional overrepresenta
www.embomolmed.org EMBO Mol Med 1, 360–370known protein quality control pathways, can lead to patholo-
gical features of neurodegenerative diseases (Nollen et al, 2004).
In a similar C. elegans screen for a-synuclein aggregation,
genome-wide RNAi screening identified modifier genes
involved in protein degradation, vesicle trafficking, lipid
metabolism and RNA metabolism. While very few individual
genes were exact orthologues of previously identified modifiers
for a-synuclein toxicity in yeast, they fell into gene classes that
showed a clear overlap. Similar to the observations in yeast, the
genes and the gene classes identified in the polyglutamine and
a-synuclein screens in C. elegans showed little overlap, again
suggesting that different processes underlie different protein-
misfolding diseases (Van Ham et al, 2008).
As they were performed in non-neuronal cells, genome-wide
screens in yeast and in C. elegans muscles have uncovered basal
cellular processes that play a role in misfolded protein pathology.
A serious concern about these results is that genes with a specific
role in neurons, the actual site where the misfolded proteins in
question cause disease, may have been missed. In an attempt to
identify these factors in C. elegans, mutant strains have been
used in which neurons, which are normally resistant to RNAi, are
made more sensitive. Such strains have been used to find
modifiers of toxicity and aggregation of misfolding disease-
related proteins, including a-synuclein, in neurons (Kuwahara
et al, 2008; Li et al, 2009). Unlike previous genome-wide screens,
these screens used a pool of genes that were preselected based on
their established role in neuronal function or for their predicted
role in neurodegeneration. These preselected screens for





g indicates classes (biological processes) described as given in the original
his class were found or not described as such in the original publication. Classes
tion analysis or statistical analysis are not indicated here.
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366functional classes as the genes found in the genome-wide screen
for a-synuclein inclusions formation in non-neuronal cells. In
particular, genes with a role in vesicle transport were identified
in both types of screens (Hamamichi et al, 2008; Kuwahara et al,
2008). Thus, this has revealed that the formation of inclusions
and the toxicity of a-synuclein are influenced by related
processes. Moreover, these findings indicate that the processes
involved in pathology include basal cellular functions that are
not exclusive to neurons, although neurons may be more
sensitive to alterations in these processes.
One major question is whether the cellular mechanisms
involved in protein-misfolding diseases are common to several
such diseases or disease-specific. With the number of related
screens performed thus far, it is now possible to compare these
screens to start answering this question. One limitation to the
comparison is that all high-throughput genetic screens for
modifiers were performed in different model organisms and
used very different screen set-ups, including different modes of
gene targeting and scoring for different phenotypes (Table 2). It
is therefore not surprising that, at first sight, the individual genes
identified hardly overlap between the different screens, but
taking a closer look at the results of these screens leads to a
different conclusion. The molecular pathways and functional
classes to which individual modifiers belong appear strikingly
similar for each individual disease-related protein (Table 3 and
Table 1 of Supporting Information).Disease-specific pathways
a-Synuclein diseases and vesicle transport defects
For instance, the vesicle transport defects identified as under-
lying the formation of a-synuclein inclusions and toxicity seem
very specific to a-synuclein pathology. Modifiers in this
functional class are hardly found in polyglutamine modifier
screens (Table 3). This specificity could be explained by the
lipid-binding properties of a-synuclein and its role in vesicle
homeostasis, and suggests that this property is important for
modulating an early toxic event (Chandra et al, 2005; Sharon
et al, 2001). This early toxic event appears to also require
aggregation of a-synuclein, because b-synuclein, a non-
aggregating counterpart of a-synuclein, as well as mutant
a-synuclein lacking the domain required for aggregation do not
cause toxicity in yeast but do share the lipid-binding property
with a-synuclein (Soper et al, 2008).
Neuronal function relies largely on the synthesis, main-
tenance, docking and fusion of synaptic vesicles. These
processes depend on subtle changes in the stability, fluidity
and curvature of the vesicle membranes, which are determined
by the lipid composition of the membranes involved. The
lipid composition of membranes changes as mammals age
(Maguire & Druse, 1989; Yehuda et al, 2002). Due to the function
and properties of in particular a-synuclein, its involvement in
vesicle homeostasis, and its interactions with lipid membranes,
altered lipid homeostasis due to old age may, therefore,
specifically be important for the development of diseases
related to a-synuclein misfolding (Welch & Yuan, 2003). 2009 EMBO Molecular MedicineRNA metabolism in polyglutamine expansion diseases
Another example of a functional gene class that is specifically
found for one type of neurodegenerative disease-related
proteins are the many RNA-processing components as modifiers
of polyglutamine toxicity and aggregation. It is noteworthy that
this class of genes was consistently found in multiple screens for
toxicity and aggregation of polyglutamine in Drosophila and C.
elegans (Table 3). There could be several explanations for a role
of general RNA metabolism in these diseases. One is that
polyglutamine proteins interact with key regulators of tran-
scription that often contain polyglutamine stretches themselves
(Nucifora et al, 2001; Zhai et al, 2005). Another aspect of RNA
metabolism that was recently shown to modify polyglutamine
pathology is microRNA (miRNA) metabolism (Bilen et al,
2006a,b). Polyglutamine aggregation and toxicity are modified
by several genes with a general role in miRNA processing, like C.
elegans argonoute-like gene alg-1, and Drosophila gene R3D1
(Bilen et al, 2006a,b; Nollen et al, 2004). Thus, RNA processing
as a polyglutamine disease-modifying pathway could involve
the processing of non-coding RNAs. In mice, the expression of
miRNAs is altered during aging, starting from middle-age
onwards (Li et al, 2009). If such a change occurs in humans
during aging, this would be consistent with miRNAs modifying
the onset of polyglutamine disease, which typically takes place
after middle-age. This potential mechanistic relation needs to be
investigated more closely. Of particular note is the discovery of
the fly orthologue of human SCA2, an RNA-binding protein, as a
modifier of SCA3 and SCA1 toxicity, showing that SCA genes
interact with each other (Al-Ramahi et al, 2007; Lessing &
Bonini, 2008). Furthermore, the observation of muscleblind
(mbl), another RNA-binding protein, as a modifier of toxicity
has led to the discovery that the SCA3 transcript itself is toxic (Li
et al, 2008). Altogether, these findings have provided explana-
tions for the specificity of RNA metabolism genes as modifiers of
polyglutamine toxicity.
Although there is much overlap in the modifiers found in the
different polyglutamine models, a recent study comparing
modifiers in two different Drosophila models shows that some
modifiers are specific and some are common to SCA1 and
huntingtin toxicity. Modifiers found in the mutant SCA1 (82Q)
flies have been tested in an Htt-128Q fly model, revealing
common and specific modifiers of toxicity (Branco et al, 2008).
The modifiers fall into three classes: (i) modifiers of toxicity in
only one model, (ii) modifiers that enhance or suppress toxicity
in both models and (iii) modifiers that function as both
enhancers and suppressors, depending on the background.
The first group contains two chaperones and two transcrip-
tion factors. The second group of modifiers include chaperones
(DNJA1), several components of the ubiquitin–proteasome
system, including Carboxyl Terminus of HSP70-interacting
protein (CHIP), and genes involved in signal transduction, RNA
metabolism and apoptosis. The last group includes one gene
involved in RNA metabolism and genes involved in signal
transduction, including Akt, which is known to phosphorylate
ataxin-1 (Branco et al, 2008). Such difference in modifier genes
for different polyglutamine proteins is in part explained by
findings that other domains of Atx1 besides the polyglutamineEMBO Mol Med 1, 360–370 www.embomolmed.org
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2008; Tsuda et al, 2005). Thus, different expanded polygluta-
mine proteins have overlapping but also protein specific
mechanisms of toxicity, which involve other, non-polygluta-
mine, segments of the disease proteins as well.Common pathways in neurodegenerative diseases
The most obvious common class of genes that act on the
pathology of all disease proteins is that involved in protein
degradation (Table 3). The finding of this gene class is not
surprising, as components of the ubiquitin proteasome system
have been found to co-localize with aggregated proteins in the
brain of patients; in fact, together with the co-localization of
molecular chaperones, this was a first hint that protein
misfolding might underlie neurodegeneration (Cummings
et al, 1998; Rubinsztein, 2006). Still, finding these protein-
degradation components powerfully confirms the validity of
using model organisms to find modifiers of misfolding disease.
In this common class of genes we still need to learn whether
they all act on all misfolded proteins or whether some of
them are specialized in mediating degradation of particular
misfolded disease proteins. E3 ubiquitin ligases, for example, of
which there are hundreds expressed in humans, each mark
specific proteins for degradation (Robinson & Ardley, 2004). It is
possible that there are E3 ligases that target all misfolded disease
proteins or that there are ligases that act on specific disease
proteins, but these remain to be identified.Pending issues
What is the initiating toxic event in each of the neurodegenerative
diseases? Is the initiating toxic event common or disease-specific?
Which modifiers act on the initiating events of each disease?
Do the modifying processes found in small model organisms play a
role in human disease? What additional modifiers are human-Gene networks
In humans it is likely that a combination of gene mutations
results in a sporadic neurodegenerative disease phenotype,
given the small contribution to disease susceptibility for each
gene found in genome wide association studies. The genetic
screens in model organisms mentioned in this review all assess
the role of a single gene at a time. Functional gene networks can
be identified by large-scale synthetic and complementation
screens and by systematic analyses of genetic dependencies
(Kornmann et al, 2009; Jonikas et al, 2009; Van Haaften et al,
2004). It will be worthwhile to perform such studies for
modifiers of protein misfolding in order to identify gene
networks that modify disease pathology.
specific, due to the larger complexity of tissues or genes?
In the case of sporadic disease, why are specific misfolded proteins
found in inclusions, and which modifying processes determine
which proteins get misfolded?
What determines the tissue specificity of protein folding disease?
If misfolding of disease proteins occur all the time, what determines
the onset of disease? Is age-of-onset dependent on an increased
load of misfolded protein or on an altered function of modifiers?
What is the toxic conformation of misfolded disease proteins and is
this form similar for different misfolding diseases?Systematic data integration
The systematic integration of the results obtained in a wide
variety of high-throughput genetic screens in different model
organisms has only just begun. The challenges are exemplified
in a small-scale analysis our laboratory performed for genome-
wide RNAi screens for a-synuclein and Q35 inclusion formation
in C. elegans (Van Ham et al, 2008). Initially, a computational
analysis of gene ontology classes of modifiers found in one such
C. elegans screen revealed no significant overrepresentation ofwww.embomolmed.org EMBO Mol Med 1, 360–370any functional class. However, analysis of the subcellular
localization of the same set of modifiers, when compared to
randomized sets of genes, discovered a clear overrepresentation
of modifiers with a role in the endomembrane system (Van
Ham et al, 2008). A parallel analysis of modifiers of
polyglutamine aggregation revealed that these modifiers func-
tioned mainly in the cytosol and in the nucleus, indicating that
there are very different ways in which cells deal with misfolded
polyglutamine proteins or misfolded a-synuclein (Van Ham
et al, 2008).
On a larger scale, a comparison of all yeast genome-wide
screens on a wide variety of phenotypes revealed that there was
generally no overlap between expression profiling studies
and genetic screens, regardless of the phenotype analysed
(Yeger-Lotem et al, 2009). However, computational comparison
of these screens using a newly developed algorithm, revealed
a regulator–effector relationship between the datasets
(Yeger-Lotem et al, 2009). These authors assembled an
integrated network model of the yeast interactome containing
protein–protein interactions, metabolic relations and protein–
DNA interactions of various levels of reliability. In this network,
they then identified high-probability paths of regulators that
potentially connect modulators identified in the genetic screens
to their differentially expressed target genes. By applying this
algorithm to the yeast screens for a-synuclein toxicity and
expression profiling, novel pathways were uncovered. For
example, the algorithm predicted the involvement of the heat
shock transcription factor Hsf-1 and Gip2 in a-synuclein
disorders and this prediction was confirmed experimentally
as overexpression of Gip2 was shown to induce an heat
shock response and to suppress the toxicity of a-synuclein
(Yeger-Lotem et al, 2009). Integrating RNAi screening data with
orthogonal evidence, for instance protein–protein interaction
data, can further help with refining the biological interpretation
of the data (Wang et al, 2009b). Together, these meta-analyses 2009 EMBO Molecular Medicine 367
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368demonstrate that a computational analysis of combined datasets
from genome-wide screens in one model organism can reveal
previously unidentified pathways with a role in protein
aggregation pathogenesis in other species.
As more data from a broader range of models are acquired,
the need for a comprehensive data integration strategy is
growing. The work done so far indicates several areas that need
special consideration when an automated computational
approach is applied: for instance, gene products need to be
carefully matched to their orthologues in various organisms,
and the number of genes screened for compared to the total
number of genes in the genome needs to be taken into account
when comparing the result statistics. The interpretation also
needs to consider that the results of individual screens tend to
provide an incomplete picture and to correct for how the genes
that were screened for were selected in each case (see also
Table 2). The most important remaining limitation, revealed by
both our own analysis of a-synuclein and Q35 inclusion
formation and the study of Yeger-Lotem et al, is the striking
heterogeneity of modifier genes. Predefined functional classes
or pathways will not always be overrepresented among them, as
they have been delimited based on unrelated physiological
processes that do not necessarily match the protein aggregation
process. Here remains a fruitful area for the application of
systems biology concepts (Kitano, 2002), which will allow
mapping the results of genetic screens onto unbiased dynamic
networks of cellular physiology to reveal the mechanistic
connections between specific cellular pathways and specific
misfolded protein pathologies.Conclusion
The pathology of different aggregation disorders in small model
organisms can be provoked by perturbations in a wide variety of
basal cellular processes. Some of these processes affect the
pathology of various disease proteins, while others appear to be
specific for one type of disease protein. Although these findings
remain to be validated in humans, they could provide an
explanation for the differences in susceptibility and age-at-onset
of aging-associated neurodegeneration, which may be due to
natural genetic variation and differences in exposure to
environmental factors that influence disease-specific modifying
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